Aspect Partners
EIKN icon

Aspect Partners’s Eikon Therapeutics EIKN Stock Holding History

Aspect Partners’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13K Buy
140
+14
+11% +$141 ﹤0.01% 572
2026
Q2 		$1.64K Buy
+126
New +$1.29K ﹤0.01% 527

Other funds holding EIKN

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Aspect Partners's EIKN Position: Q3 2026 in Review

Aspect Partners increased its Eikon Therapeutics (EIKN) stake by 11% in Q3 2026, buying an estimated $141 and bringing the position to 140 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #572.

Aspect Partners first reported a position in EIKN in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.64K in Q2 2026. 10 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

  • Aspect Partners held 140 shares of Eikon Therapeutics worth $1.13K as of Q3 2026.
  • Aspect Partners bought 14 Eikon Therapeutics shares in Q3 2026, an estimated $141.
  • Eikon Therapeutics made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #572 holding.
  • Aspect Partners first reported a position in Eikon Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Aspect Partners's Eikon Therapeutics position peaked at $1.64K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.